| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Quebec, Canada H3T 1E2 [R. A., Z-Y. X., V. B., J. B., Y. Y., A. M., M. A. A-J., L. P.], and Pathology and Human Genetics, McGill University and Cytogenetics, McGill University Hospital Center, Montreal Children’s Hospital, Montreal, Quebec, Canada H3H 1P3 [F-Y. H., A. M. V. D.]
We have recently completed screening of the National Cancer Institute human tumor cell line panel and demonstrated that among four nucleotide excision repair proteins (XPA, XPB, XPD, and ERCC1), only the TFIIH subunit XPD endogenous protein levels correlate with alkylating agent drug resistance. In the present study, we extended this work by investigating the biological consequences of XPD overexpression in the human glioma cell line SK-MG-4. Our results indicate that XPD overexpression in SK-MG-4 cells leads to cisplatin resistance without affecting the nucleotide excision repair activity or UV light sensitivity of the cell. In contrast, in SK-MG-4 cells treated with cisplatin, XPD overexpression leads to increased Rad51-related homologous recombinational repair, increased sister chromatid exchanges, and accelerated interstrand cross-link removal. Moreover, we present biochemical evidence of an XPD-Rad51 protein interaction, which is modulated by DNA damage. To our knowledge, this is the first description of functional cross-talk between XPD and Rad51, which leads to bifunctional alkylating agent drug resistance and accelerated removal of interstrand cross-links.
This article has been cited by other articles:
|
|
 |
|
  Y. Yoshimoto, C. K. Augustine, J. S. Yoo, P. A. Zipfel, M. A. Selim, S. K. Pruitt, H. S. Friedman, F. Ali-Osman, and D. S. Tyler Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents Mol. Cancer Ther., May 1, 2007; 6(5): 1492 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zorbas-Seifried, M. A. Jakupec, N. V. Kukushkin, M. Groessl, C. G. Hartinger, O. Semenova, H. Zorbas, V. Yu. Kukushkin, and B. K. Keppler Reversion of Structure-Activity Relationships of Antitumor Platinum Complexes by Acetoxime but Not Hydroxylamine Ligands Mol. Pharmacol., January 1, 2007; 71(1): 357 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Lin and S. B. Howell DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance Mol. Cancer Ther., May 1, 2006; 5(5): 1239 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. de las Penas, M. Sanchez-Ronco, V. Alberola, M. Taron, C. Camps, R. Garcia-Carbonero, B. Massuti, C. Queralt, M. Botia, R. Garcia-Gomez, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients Ann. Onc., April 1, 2006; 17(4): 668 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z.-Y. Xu, M. Loignon, F.-Y. Han, L. Panasci, and R. Aloyz Xrcc3 Induces Cisplatin Resistance by Stimulation of Rad51-Related Recombinational Repair, S-Phase Checkpoint Activation, and Reduced Apoptosis J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 495 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Okuda, X. Lin, J. Trang, and S. B. Howell Suppression of hREV1 Expression Reduces the Rate at Which Human Ovarian Carcinoma Cells Acquire Resistance to Cisplatin Mol. Pharmacol., June 1, 2005; 67(6): 1852 - 1860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Wu, X. Lin, T. Okuda, and S. B. Howell DNA Polymerase {zeta} Regulates Cisplatin Cytotoxicity, Mutagenicity, and The Rate of Development of Cisplatin Resistance Cancer Res., November 1, 2004; 64(21): 8029 - 8035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Taron, R. Rosell, E. Felip, P. Mendez, J. Souglakos, M. S. Ronco, C. Queralt, J. Majo, J. M. Sanchez, J. J. Sanchez, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer Hum. Mol. Genet., October 1, 2004; 13(20): 2443 - 2449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yoshida and T. Morita Control of Radiosensitivity of F9 Mouse Teratocarcinoma Cells by Regulation of Histone H2AX Gene Expression using a Tetracycline Turn-Off System Cancer Res., June 15, 2004; 64(12): 4131 - 4136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Jensen and P. M. Glazer Cell-interdependent cisplatin killing by Ku/DNA-dependent protein kinase signaling transduced through gap junctions PNAS, April 20, 2004; 101(16): 6134 - 6139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wu, W. Fan, S. Xu, and Y. Zhou Sensitization to the Cytotoxicity of Cisplatin by Transfection with Nucleotide Excision Repair Gene Xeroderma Pigmentosun Group A Antisense RNA in Human Lung Adenocarcinoma Cells Clin. Cancer Res., December 1, 2003; 9(16): 5874 - 5879. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
